Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05160597|
Recruitment Status : Recruiting
First Posted : December 16, 2021
Last Update Posted : February 17, 2022
|Condition or disease||Intervention/treatment||Phase|
|Prostate Carcinoma||Procedure: Biopsy of Prostate Other: Gallium Ga 68 Gozetotide Procedure: Transrectal Ultrasonography Guided Biopsy||Early Phase 1|
I. To assess the detection rate of clinically significant prostate cancer (Gleason score 7 or more) in patients with focal gallium Ga 68 gozetotide (68Ga-PSMA-11) uptake within the prostate.
SCREENING PROCEDURE: Patients receive 68Ga-PSMA-11 intravenously (IV) and 50-100 minutes later, undergo a PET/CT scan. Only patients with 68Ga-PSMA-11 uptake within the prostate proceed to image-guided biopsy.
IMAGE-GUIDED BIOPSY: Patients undergo experimental image-guided prostate biopsy using PET/CT images obtained during screening procedure during a standard of care transrectal ultrasonography guided biopsy (TRUS).
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluation of 68Ga-PSMA-11 PET Guided Prostate Biopsy in Men With Suspicion of Clinically Significant Prostate Cancer and Prior Negative/Inconclusive Biopsy: A Prospective Exploratory Study|
|Actual Study Start Date :||January 13, 2022|
|Estimated Primary Completion Date :||July 31, 2024|
|Estimated Study Completion Date :||July 31, 2025|
Experimental: Diagnostic (68Ga-PSMA-11, image-guided prostate biopsy)
SCREENING PROCEDURE: Patients receive 68Ga-PSMA-11 IV and 50-100 minutes later, undergo a PET/CT scan. Only patients with 68Ga-PSMA-11 uptake within the prostate proceed to image-guided biopsy.
IMAGE-GUIDED BIOPSY: Patients undergo experimental image-guided prostate biopsy using PET/CT images obtained during screening procedure during a standard of care TRUS.
Procedure: Biopsy of Prostate
Undergo image-guided prostate biopsy
Other: Gallium Ga 68 Gozetotide
Procedure: Transrectal Ultrasonography Guided Biopsy
Undergo standard of care TRUS
- Detection rate of clinically significant prostate cancer [ Time Frame: Up to 3 years ]Defined as the percentage of clinically significant prostate cancer (Gleason score 7 or more) in patients with focal 68Ga-PSMA-11 uptake within the prostate
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05160597
|Contact: Wesley Armstrongemail@example.com|
|Contact: Stephanie Lira||310-206-0596||StephanieLira@mednet.ucla.edu|
|United States, California|
|UCLA / Jonsson Comprehensive Cancer Center||Recruiting|
|Los Angeles, California, United States, 90095|
|Contact: Jeremie Calais firstname.lastname@example.org|
|Principal Investigator: Jeremie Calais|
|Principal Investigator:||Jeremie Calais||UCLA / Jonsson Comprehensive Cancer Center|